• Publications
  • Influence
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
TLDR
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCa2 mutation. Expand
Rethinking ovarian cancer: recommendations for improving outcomes
TLDR
Nine major recommendations that should be taken to improve the outcome for women with ovarian cancer are outlined in this Opinion article. Expand
Ovarian cancer: strategies for overcoming resistance to chemotherapy
TLDR
A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved. Expand
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
TLDR
CYP17 blockade by abiraterone acetate is safe and has significant antitumor activity in CRPC, and data confirm that CRPC commonly remains dependent on ligand-activated AR signaling. Expand
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
TLDR
A significant association between ERG rearrangements in therapy-naive tumors, CRPCs, and CTCs and magnitude of prostate-specific antigen decline is reported and indicates that hormone-regulated expression of ERG persists in CRPC. Expand
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
TLDR
YP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven. Expand
Beyond chemotherapy: targeted therapies in ovarian cancer
TLDR
The introduction of novel targeted therapies will have a major impact on the management of ovarian cancer and allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine. Expand
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
TLDR
Sorafenib has significant disease-stabilizing activity in metastatic renal cell carcinoma and is tolerable with chronic daily therapy. Expand
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
TLDR
There is strong and confirmatory evidence from two large randomized phase III trials to support paclitaxel-cisplatin as the new standard regimen for treatment of patients with advanced ovarian cancer. Expand
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
TLDR
A phase II trial of a combination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck found substantial objective responses, including a high proportion of complete responses. Expand
...
1
2
3
4
5
...